Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial of tanespimycin (17-N-allylamino-17-demethoxygeldanamycin) with or without rituximab in relapsed B-cell chronic lymphocytic leukemia or prolymph…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Prolymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)
• tanespimycin (17-N-allylamino-17-demethoxygeldanamycin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 | Status: TERMINATED